US2002131992A1PendingUtilityA1

Method and product for treating cancer in pets

29
Priority: Mar 12, 2001Filed: Dec 21, 2001Published: Sep 19, 2002
Est. expiryMar 12, 2021(expired)· nominal 20-yr term from priority
Inventors:Nongnuch Inpanbutr
A23K 20/174A23K 40/30A61K 31/59A23K 50/40A23K 50/48
29
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pet food containing vitamin D analogs for use in treatment of cancer in pets, such as dogs and cats, is described. Also described is a method for treating pets, such as dogs and cats, for cancer by feeding the pet a pet food containing at least one vitamin D analog.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of treating cancer in a dog, comprising the step of feeding the dog a therapeutic agent comprising a vitamin D analog.  
     
     
         2 . The method of  claim 1 , wherein the vitamin D analog is selected from the group consisting of 1α,25-(OH) 2 D 3 , 1α,25-(OH) 2 -16-ene-23-yne-D 3  (analog V), and 1α,25-(OH) 2 -22,24-diene-24,26,27-trihomo-D 3  (EB 1089) and stereoisomers thereof.  
     
     
         3 . The method of  claim 2 , wherein the vitamin D analog is 1α,25-(OH) 2 D 3  and stereoisomers thereof.  
     
     
         4 . The method of  claim 2 , wherein the vitamin D analog is 1α,25-(OH) 2 -16-ene-23-yne-D 3  (analog V) and stereoisomers thereof.  
     
     
         5 . The method of  claim 2 , wherein the vitamin D analog is 1α,25-(OH) 2 -22,24-diene-24,26,27-trihomo-D 3  (EB 1089) and stereoisomers thereof.  
     
     
         6 . The method of  claim 1 , wherein the vitamin D analog is administered in combination with a bone agent, a cytotoxic agent, an immuno response regulating agent, an antiinflammatory agent or combinations thereof.  
     
     
         7 . The method of  claim 1  wherein the vitamin D analog is administered orally in encapsulated form in a liquid vehicle ingestible by the dog.  
     
     
         8 . The method of  claim 1 , wherein the dog is fed from about 0.025 to about 500 nmol/kg of body weight of the patient per day of the vitamin D analog.  
     
     
         9 . The method of  claim 8 , wherein the dog is fed from about 0.025 to about 100 nmol/kg of body weight of the patient per day of the vitamin D analog.  
     
     
         10 . The method of  claim 9 , wherein the dog is fed from about 0.025 to about 10 nmol/kg of body weight of the patient per day of the vitamin D analog.  
     
     
         11 . The method of  claim 9 , wherein the dog is fed from about 0.025 to about 1.0 nmol/kg of body weight of the patient per day of the vitamin D analog.  
     
     
         12 . The method of  claim 1 , wherein the dog is fed a therapeutically efficacious dosage of a vitamin D analog.  
     
     
         13 . A food for dogs comprising a vitamin D analog.  
     
     
         14 . The food of  claim 13 , wherein the vitamin D analog is selected from the group consisting of 1α,25-(OH) 2 D 3 , 1α,25-(OH) 2 -16-ene-23-yne-D 3  (analog V), and 1α,25-(OH) 2 -22,24-diene-24,26,27-trihomo-D 3  (EB 1089) and stereoisomers thereof.  
     
     
         15 . The food of  claim 13 , wherein the vitamin D analog is 1α,25-(OH) 2 D 3  and stereoisomers thereof.  
     
     
         16 . The food of  claim 13 , wherein the vitamin D analog is 1α,25-(OH) 2 -16-ene-23-yne-D 3  (analog V) and stereoisomers thereof.  
     
     
         17 . The food of  claim 13 , wherein the vitamin D analog is 1α,25-(OH) 2 -22,24-diene-24,26,27-trihomo-D 3  (EB 1089) and stereoisomers thereof.

Join the waitlist — get patent alerts

Track US2002131992A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.